Investor relations

INOFEA welcomes mutually beneficial collaborations with industries and biotech companies.

Our goal is to move further from a local spin-off to an international product based company, through constant innovation and investment in high value-added solutions.

Our main strengths:

  • Extensive experience in innovative biotech research, development and implementation, in which we invest annually;
  • A team of experienced researchers and scientific advisors, with strong biotech background;
  • Proprietary technology to formulate enzymes at industrial scale;
  • Numerous applications of our patented platform technology, in high-valuelines of business;

A number of important investors trusted us to rise to the expectations: EVA is our historic investor, together with a number of Swiss business angels.

Inofea - Company presentation from INOFEA

Board of directors



Stéphane Rousset, Chairman of the Board is a Business Angel, mentor, advisor, and Board member. 
He focuses on Swiss technology startups. His corporate career was in the Information and Communications Technology industry.
He was a general manager with focus on go-to-market and sales. He held C-level positions at Fujitsu and Oracle, after various leadership positions at Digital Equipment, AT&T, and Global One.
He is an alumnus of EPFL, the University of California at Berkeley, and INSEAD.


Dr. Werner M. Enz is Chief Executive Officer of EVA, the Basel Life Science start-up agency, and also of the Basel Inkubator, a mandate from the University of Basel and the Fachhochschule Nordwestschweiz (FHNW).
He held various senior executive positions with Roche in Basel, Canada and Germany, including running Roches largest business unit in oncology, immunology and transplant medicine. After a merger project with Rhône Poulenc Rorer (today Sanofi) in Sweden, he worked for Abbott as Commercial Director Europe in the USA and Divisional Head Hospital business in Switzerland. 
Dr. Enz also worked for a number of innovative startups and mid-sized B2B technology companies in life science, leading late stage clinical and business development as well as commercial operations, including as country manager and CEO. 
He holds a Doctorate in Medicine from the University of Bern, Switzerland, and an MBA from Edinburgh Business School, Scotland, UK.


Dr. Martin Riediker:
- Education in Chemistry at the ETHZ and Princeton University/USA
- Business und General Management Education at Harvard University/USA
- 30 years’ experience in the chemical industry
- Member of the Boards of Plaxica (Bio-based Chemicals), Polymetrix (PET), Micromacinazione
(Pharma), INOFEA (Biocatalysis)
- Member of the Commission for Education and Research of economiesuisse
- Member of the SCCER Steering Committee
- President of the Steering Committee of the National Research Program 66: Resource Wood
- President Engineering Sciences of the Commission for Technology and Innovation
- Born in Canton Zürich, married, 3 children, now living in Canton Baselland


Dr. Yves Dudal is a biotech engineer by training (National Institute for Applied Sciences, INSA Toulouse, France) and received his PhD in chemical engineering from Polytechnique Montréal, Canada in 2000. Yves has worked 8 years as academic researcher in Montpellier, France, leading to the foundation of his first start-up company in 2010, which was taken over by a european group in 2015. He is now engaged in the development of INOFEA.

Industrial advisory board

INOFEA established its industrial advisory board to ensure that our R&D activity is relevant and effective, and to strengthen INOFEA’s ties to the industrial world. Our advisory board is comprised of experienced executives from life science companies, members of renowned scientific institutions with a strong biotech background.


Dr. Anne Timm,

Education in Biology at the Technical University of Darmstadt 27 years of experience in the chemical industry Various positions in R&D, business development, project management, marketing, sales leadership and key account management in Ciba-Geigy, Ciba Specialty Chemicals and Clariant.

Experience with a broad range of chemical raw materials for the personal care-, home care-, plastic and coating-, textile-, medical device-, pharma- and crop protection-industry.

Current position as BU Head Schoeller Medical


Hans-Peter Meyer holds a PhD in microbiology from the University of Fribourg (Switzerland). After 3 years of post-gradual and post-doctoral studies in Stockholm, at the University of Pennsylvania (Philadelphia) and Lehigh University (Bethlehem, USA), he became a member of Prof. Armin Fiechter’s team in 1982 as group leader and lecturer at the Swiss Federal Institute of Technology (ETH) in Zürich for four years before joining Lonza in Visp (Switzerland) in 1986. Hans-Peter Meyer retired after 30 years in the industry as Lonza VP “Strategic Projects Biotechnology” and after a number of other executive positions in R&D, manufacturing, sales & marketing. After his retirement in 2014, he joined the faculty of the Applied University Western in Sion, remains an expert at the Commission of Technology and Innovation (CTI) of the Swiss Federal Confederation, member of the board CoEBio3 Manchester UK, member of the Swiss Academy of Engineering Sciences (transfer group), member of the International Advisory board of VTT in Finland and the Institute of Biotechnology of the Zürich Applied University.


Georg Wiebecke, Ph.D.

Georg Wiebecke studied Chemistry at the ETH Zürich and the Imperial College in London. He then worked with McKinsey & Co., Zurich, serving clients in life sciences and chemical industries and rising to Senior Engagement Manager. Subsequently he worked in industry and founded his first consultancy company.

In 1996 Georg joined Hoffmann-La Roche to run a global productivity program in Technical Operations and the integration of a major acquisition in R&D. He then managed the global supply chain department, substantially improving service levels and reducing inventories after the introduction of SAP. Next, he led Global Engineering, managing Roche’s major capital investment projects. In 2004 he became president of Roche Colorado Corporation, Roche’s center of excellence for peptides APIs, expanding its reach from group supplier to a contract R&D and manufacturing business. Georg then returned to Basel to lead the chemical plant there, and subsequently Roche’s global chemical manufacturing.

In 2012 Georg moved to the food industry to lead the Global Operations of Givaudan’s Flavours division, building and starting up major new plants, introducing Lean Manufacturing globally, and implementing major organizational changes. In 2015, Georg changed to life sciences again founding Wiebecke Consulting AG: This new firm is specializing on start-ups, change of ownership situations and operations strategy with significant value coming from product R&D, manufacturing an supply chain.

Inofea timeline 

[2017] Raising CHF 400-800k, series A+

[2016] Top 100 Swiss start-ups

[2014] Swiss CTI Label granted [2014] Our seed financing round and the legal maturing of the company from a GmbH to an AG